Russell Beyer - Oct 18, 2021 Form 4 Insider Report for SAB Biotherapeutics, Inc. (SABS)

Role: Chief Financial Officer
Signature: /s/ Russell Beyer
Stock symbol: SABS
Transactions as of: Oct 18, 2021
Transactions value $: $25,458
Form type: 4
Date filed: 11/16/2021, 02:09 PM
Next filing: Oct 22, 2021

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	SABS	Common Stock	Award	$25K	+2.48K		$10.10^*	2.48K	Oct 18, 2021	Direct	F1
transaction	SABS	Common Stock	Award	$1.5K	+149		$10.08^*	149	Sep 28, 2021	By spouse	F1
transaction	SABS	Common Stock	Award	$1K	+129	+86.58%	$7.78^*	278	Oct 25, 2021	By spouse
transaction	SABS	Common Stock	Sale	-$2.2K	-278	-100%	$7.90^*	0	Oct 26, 2021	By spouse	F2
transaction	SABS	Common Stock	Award	$50.40	+5		$10.07^*	5	Sep 28, 2021	By daughter	F1
transaction	SABS	Common Stock	Award	$101	+10	+200%	$10.08^*	15	Sep 29, 2021	By daughter	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.
F2	The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.

Content

This transaction occurred prior to the business combination pursuant to the Agreement and Plan of Merger, dated June 21, 2021 and as amended August 12, 2021, by and among Big Cypress Acquisition Corp., Big Cypress Merger Sub Inc., and SAB Biotherapeutics, Inc. ("Issuer"). The reporting person's obligation to disclose this transaction occurred upon the consummation of the business combination.

The sale of Issuer common stock by the reporting person's spouse reported herein was matchable under Section 16(b) of the Securities Exchange Act of 1934, to the extent of 278 shares, with the purchase of 278 shares of Issuer's common stock as also reported herein. The reporting person has paid to Issuer, upon settlement of the sale, $15.48, representing the full amount of the profit realized in connection with the short-swing transaction.